Merus Investor Relations Material
Latest events
Investor Update
Merus
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Merus N.V.
Access all reports
Merus N.V. is a clinical-stage immuno-oncology company focused on developing innovative bispecific antibody therapeutics. The company specializes in creating full-length human multispecific antibodies known as Biclonics and Triclonics, which are designed to engage multiple targets, offering new approaches to treat various cancers. Merus has a broad pipeline, including candidates in different stages of clinical trials targeting solid tumors and hematologic malignancies. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the Nasdaq.
Key slides for Merus N.V.
Study Update
Merus N.V.
Investor Update
Merus N.V.
Latest articles
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
Ticker symbol
MRUS
Country
🇺🇸 United States